Stock Events

Stock Events

Cel 

$0
2
+$0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

28
FEB 27
Dividend Ex
Estimated
 

Dividends

0%Dividend Yield
Feb 26
$0.68
Feb 25
$0.68
May 24
$0.7
May 23
$0.59
May 22
$0.69
10Y Growth
N/A
5Y Growth
-3.91%
3Y Growth
-0.76%
1Y Growth
-2.9%

Earnings

11AprExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
0.41
0.66
0.9
1.14
Expected EPS
N/A
Actual EPS
N/A

Financials

4.83%Profit Margin
Profitable
2020
2021
2022
2023
159.15MRevenue
7.69MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CLCPF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics focuses on gene editing technologies, directly competing with Cel's gene therapy approaches.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine is involved in genome editing technology, similar to Cel's focus on gene therapy for treating diseases.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is a key player in CRISPR/Cas9 technology, competing in the same gene editing space as Cel.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, gene editing, and gene regulation, overlapping with Cel's market.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical offers gene therapy products for various genetic disorders, competing in the same therapeutic areas as Cel.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals works on RNAi therapeutics, a different but competing approach to Cel's gene-based therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals incorporates CRISPR gene editing in some of its drug development, positioning it as a competitor in the gene therapy field.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is involved in gene therapy through its rare disease unit, making it a competitor by targeting similar diseases as Cel.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the cell therapy space, relevant to Cel's focus on gene and cell therapies.

About

CEL Corporation provides consulting services on land utilization. The company also engages in the business related to design and construction, civil engineering works; property management, building leasing, and management and operations; real estate sales, leasing, exchange and its agency, and mediation; and building remodeling and maintenance. In addition, it is involved in the business related to manufacturing and processing of steel frame members and materials for construction activities, and provision of apartment management services. The company was founded in 1993 and is based in Tokyo, Japan.
Show more...
CEO
Country
JP
ISIN
JP3423610009

Listings

TSE
JP
5078.TSE

0 Comments

Share your thoughts

FAQ

What is Cel stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cel stocks are traded under the ticker CLCPF.
What is Cel revenue for the last year?▼
Cel revenue for the last year amounts to 159.15M USD.
What is Cel net income for the last year?▼
CLCPF net income for the last year is 7.69M USD.
Does Cel pay dividends?▼
Yes, CLCPF dividends are paid semi-annual. The last dividend per share was 0.68 USD. As of today, Dividend Yield (FWD)% is 0%.
In which sector is Cel located?▼
Cel operates in the Other sector.
When did Cel complete a stock split?▼
Cel has not had any recent stock splits.